Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward
- PMID: 17920565
- DOI: 10.1016/j.biopsych.2007.07.020
Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward
Abstract
Background: The recreational drug, Salvinorin A, derived from the plant of Salvia divinorum, is a potent and selective kappa-opioid receptor agonist. The abuse of selective k-agonists is a novel phenomenon, the mechanism of which is not fully understood.
Methods: We investigated salvinorin A given SC on the conditioned place preference (.05-160 microg/kg) and intracerebroventricular (ICV) self-administration (.01-1 microg/infusion) paradigms, in Wistar rats.
Results: The present results demonstrate the rewarding effects of Salvinorin A in a range of doses between .1 and 40 microg/kg SC for conditioned place preference test and .1-.5 microg/infusion for ICV self-administration. Highest doses (160 microg/kg for conditioned place preference test and 1 microg/infusion for ICV self-administration) were aversive. The rewarding effect was antagonized by intraperitoneal (IP) pretreatment with the cannabinoid CB(1) receptor antagonist, rimonabant [N-piperidino-5-(4-chlorophenyl)1-(2,4-dichloro phenyl)-4 methyl pyrazole 3-carboxamide] (1 mg/kg), and the kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI) (10 mg/kg). In the shell of nucleus accumbens, dopamine extracellular levels were increased after administration of salvinorin A (40 microg/kg SC), reaching a maximum value of about 150%.
Conclusions: These data provide the demonstration of the rewarding effects of Salvinorin A through an interaction between kappa-opioid and (endo)cannabinoid system in rats.
Similar articles
-
Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.Psychopharmacology (Berl). 2007 Mar;190(4):441-8. doi: 10.1007/s00213-006-0639-1. Epub 2007 Jan 12. Psychopharmacology (Berl). 2007. PMID: 17219220
-
Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.Br J Pharmacol. 2009 Jul;157(5):844-53. doi: 10.1111/j.1476-5381.2009.00230.x. Epub 2009 May 5. Br J Pharmacol. 2009. PMID: 19422370 Free PMC article.
-
Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.Eur J Pharmacol. 2004 Dec 3;506(1):63-9. doi: 10.1016/j.ejphar.2004.10.043. Eur J Pharmacol. 2004. PMID: 15588625
-
Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.Planta Med. 2007 Aug;73(10):1039-46. doi: 10.1055/s-2007-981566. Epub 2007 Jul 12. Planta Med. 2007. PMID: 17628834 Review.
-
Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.Neuropharmacology. 2005 Jun;48(8):1105-16. doi: 10.1016/j.neuropharm.2005.03.016. Neuropharmacology. 2005. PMID: 15878779 Review.
Cited by
-
Clinical applications of hallucinogens: A review.Exp Clin Psychopharmacol. 2016 Aug;24(4):229-68. doi: 10.1037/pha0000084. Exp Clin Psychopharmacol. 2016. PMID: 27454674 Free PMC article. Review.
-
Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.Psychopharmacology (Berl). 2015 Jan;232(1):91-100. doi: 10.1007/s00213-014-3641-z. Epub 2014 Jun 13. Psychopharmacology (Berl). 2015. PMID: 24923984
-
Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan.J Food Drug Anal. 2014 Sep;22(3):370-378. doi: 10.1016/j.jfda.2014.01.017. Epub 2014 Feb 16. J Food Drug Anal. 2014. PMID: 28911428 Free PMC article.
-
Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.ACS Chem Neurosci. 2013 Aug 21;4(8):1137-50. doi: 10.1021/cn400090q. Epub 2013 Aug 6. ACS Chem Neurosci. 2013. PMID: 23883191 Free PMC article. Review.
-
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:51-60. doi: 10.1016/j.pnpbp.2015.01.001. Epub 2015 Jan 12. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25592680 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical